Back to Stocks

TARS

Tarsus Pharmaceuticals, Inc.
7 filings tracked
healthcarebiotechnologySMALL ($300M-2B)

Company Intelligence Hub

Filing history, signal momentum, and bull/bear evolution

Chronological Filing Evolution (Click to filter / toggle)

Thesis (Bull Case Evolution)

Tarsus Pharmaceuticals is demonstrating a textbook commercial scale-up, highlighted by a staggering 85% year-over-year increase in net product sales to $145.4 million in Q1 2026.…

Bullish Outlook

Antithesis (Bear Case / Structural Risks)

Despite the headline growth, Tarsus faces a precarious structural dependency.…

Risk Factors

Read the full bull/bear analysis

You are reading the free preview. Start a free trial to unlock the complete bull & bear analysis for every TARS filing.

Start Free Trial

Synthesis (Verdict & Resolution)

The Q1 2026 filing reveals a company at a critical inflection point. Tarsus has proven it can generate massive top-line growth and maintain elite margins, but it has yet to achieve GAAP profitability. The synthesis of the data suggests a high-reward trade-off: the bull case rests on the belief that the commercial ramp is sustainable and that the 2027 pipeline catalysts will diversify the risk. Conversely, the bear case highlights that the company is essentially a 'single-point-of-failure' business due to its API and customer concentration. Ultimately, the filing shows a transition from a speculative biotech to a commercial entity. While the $388.7 million liquidity cushion provides a safety net, the massive SG&A spend indicates that the cost of acquiring market share remains high. The coming quarters will determine if Tarsus can optimize its sales spend and diversify its customer base before the 2027 catalysts arrive.

Selected Quarter

Core Takeaway

Tarsus is successfully scaling XDEMVY with 85% YoY growth, but remains vulnerable to a few key customers and a single API supplier.

Investor Lens

The trade-off is between the high-growth commercial trajectory and the binary risk of supply chain or customer loss.

Watch Next

Top-line data for TP-04 and TP-05 expected in H1 2027.

View Full SEC Report

Signal Momentum Chart

Quarterly net bull/bear signal ratio. Click nodes to select a quarter.

BULLISH (+1.0)NEUTRAL (0.0)BEARISH (-1.0)+0.57Q2 '26 (10-Q)

Signal Timeline

Active Filters:Quarter: Q2 '26 (10-Q)
bullishMay 6

Revenue surged 85% YoY to $145.4 million driven by XDEMVY sales.

earnings beat
90%
bullishMay 6

Gross margins remained consistently high at 94%.

margin expansion
80%
neutralMay 6

Maintains a $75M credit facility with Pharmakon Advisors.

debt restructure
50%
bullishMay 6

Revenue surged 85% YoY to $145.4 million driven by XDEMVY sales.

earnings beat
90%
bullishMay 6

Gross margins remained consistently high at 94%.

margin expansion
80%
neutralMay 6

Maintains a $75M credit facility with Pharmakon Advisors.

debt restructure
50%
bullishMay 6

Revenue surged 85% YoY to $145.4 million driven by XDEMVY sales.

earnings beat
90%
bullishMay 6

Gross margins remained consistently high at 94%.

margin expansion
80%
neutralMay 6

Maintains a $75M credit facility with Pharmakon Advisors.

debt restructure
50%
bullishMay 6

Revenue surged 85% YoY to $145.4 million driven by XDEMVY sales.

earnings beat
90%
bullishMay 6

Gross margins remained consistently high at 94%.

margin expansion
80%
neutralMay 6

Maintains a $75M credit facility with Pharmakon Advisors.

debt restructure
50%
bullishMay 6

Revenue surged 85% YoY to $145.4 million driven by XDEMVY sales.

earnings beat
90%
bullishMay 6

Gross margins remained consistently high at 94%.

margin expansion
80%
neutralMay 6

Maintains a $75M credit facility with Pharmakon Advisors.

debt restructure
50%
bullishMay 6

Revenue surged 85% YoY to $145.4 million driven by XDEMVY sales.

earnings beat
90%
bullishMay 6

Gross margins remained consistently high at 94%.

margin expansion
80%
neutralMay 6

Maintains a $75M credit facility with Pharmakon Advisors.

debt restructure
50%
bullishMay 6

Revenue surged 85% YoY to $145.4 million driven by XDEMVY sales.

earnings beat
90%
bullishMay 6

Gross margins remained consistently high at 94%.

margin expansion
80%
neutralMay 6

Maintains a $75M credit facility with Pharmakon Advisors.

debt restructure
50%

Filing History

10-QMay 6, 2026
Expand Sequence

The Q1 2026 filing reveals a company at a critical inflection point. Tarsus has proven it can generate massive top-line growth and maintain elite margins, but it has yet to achieve GAAP profitability. The synthesis of the data suggests a high-reward trade-off: the bull case rests on the belief that the commercial ramp is sustainable and that the 2027 pipeline catalysts will diversify the risk. Conversely, the bear case highlights that the company is essentially a 'single-point-of-failure' business due to its API and customer concentration. Ultimately, the filing shows a transition from a speculative biotech to a commercial entity. While the $388.7 million liquidity cushion provides a safety net, the massive SG&A spend indicates that the cost of acquiring market share remains high. The coming quarters will determine if Tarsus can optimize its sales spend and diversify its customer base before the 2027 catalysts arrive.

Disclaimer: The synthesis provided is generated by AI models and should not be construed as investment advice. Analysis is based solely on regulatory data present at the time of publication. Consult a financial advisor for specific investment strategies.